Alnylam and Inceptive Sign 2 Billion Dollar AI Deal
Alnylam Pharmaceuticals has entered a collaboration with Inceptive to utilize artificial intelligence for the discovery of RNA-based medicines. The deal includes a thirty million dollar upfront payment and potential milestone payments as the firms combine data with AI models to accelerate drug development.
ALNYLAM PHARMACEUTICALS INC partnered with Inceptive on June 3 in a drug discovery deal worth up to $2 billion. The collaboration aims to accelerate the development of RNA-based medicines using generative AI models. This agreement aligns with Alnylam's 2030 strategy to scale its therapeutic pipeline through advanced computational design.
### Upfront Cash and Milestone Incentives ALNYLAM PHARMACEUTICALS INC will pay $30 million upfront, comprising a cash payment and an equity investment in Inceptive. Additional payments are tied to specific pre-clinical, regulatory, and commercial sales milestones. This structure allows ALNYLAM PHARMACEUTICALS INC to leverage the technology of Inceptive while mitigating early-stage financial risk.
